SCH-58235

DRUG2 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Heart DiseasesLipoidosisMetabolism, Inborn Errors

Phase 2

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

CompletedNCT00045812

National Heart, Lung, and Blood Institute (NHLBI)Lipoidosis

Start: 2001-03-31End: 2004-04-30Target: 5Updated: 2008-03-04

Phase 3

Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

CompletedNCT00099996

National Heart, Lung, and Blood Institute (NHLBI)Heart Diseases, Metabolism, Inborn Errors

Start: 2004-12-31End: 2005-12-31Target: 3Updated: 2008-03-04